N uclear medicine studies such as bone scan, lymphoscintigraphy, and fluorine 18 ( 18 F) fluorodeoxyglucose (FDG) PET/CT may be performed in patients with breast cancer for staging and treatment planning. Focal or diffuse radiotracer uptake can also be incidentally found within the breast in patients without breast cancer. These findings may be clinically relevant and could correlate with mammogram or breast US to help confirm a suspected diagnosis, which may save the patient additional workup and anxiety. Certain lesions may demonstrate avid uptake of one radiotracer but fail to have any uptake of another. Familiarity with the expected level of radiotracer uptake of specific breast lesions may also aid in making the correct diagnosis. There are PET radiotracers including gallium 68 ( 68 Ga) tetraazacyclododecane tetraacetic acid octreotate (DOTATATE), 18 F-fluciclovine, and 68 Ga-prostate-specific membrane antigen (PSMA) that may also demonstrate incidental breast uptake. Reviewing pathologic correlation of these incidental lesions can be helpful in future imaging interpretation.The goals of this review are to demonstrate the spectrum of breast lesions that can be detected on various molecular imaging studies, present relevant features on correlative anatomic imaging, and help the reader obtain additional imaging when warranted. This institutional review boardapproved, Health Insurance Portability and Accountability Act-compliant pictorial essay will provide an overview of various planar, SPECT, and PET nuclear medicine studies and the breast lesions that can be detected at each.